ODAC recommends go-slow approach for olaparib approval

By Mari SerebrovWashington Editor

Wednesday, June 25, 2014

If the FDA follows the advice of its Oncologic Drugs Advisory Committee (ODAC), it will not be approving Astrazeneca plc's olaparib anytime soon as a maintenance therapy for BRCA-mutated ovarian cancer.